Arch Biopartners has announced that the drug AB569 designed to treat pulmonary infections with P. aeruginosa completed successful pre-clinical in vitro and in vivo validation tests, according to Lung Disease News.

From a therapeutic viewpoint, a number of antibiotics are utilized to treat infections with P. aeruginosa, including but not limited to aminoglycosides, quinolones, and carbapenems. However, P. aeruginosa has an immense potential to develop resistance against antibiotics as its genome contains the largest resistance island with more than 50 resistance genes. Particularly, the mucoid form of P. aeruginosa usually present in lungs of CF patients is a very difficult infection to treat due to its high resistance to antibiotics as well as phagocyte-mediated killing. As a result, an urgent therapy is required and the new drug AB569 has the characteristics to deal with mucoid and nonmucoid P. aeruginosa infections which are resistant to traditional antibiotics.

In recent studies, Arch Biopartners Inc revealed that AB569 showed significant efficiency against P. aeruginosa including in vivo testing on mice model affected with chronic pulmonary infection. Because these results are very promising, the company’s research team is planning to pursue trials on human pulmonary CF patients infected with P. aeruginosa to test the safety and efficacy of AB569. They are currently evaluating the appropriate regulatory and toxicology procedures before starting the tests.

The company believes that AB569 looks a very promising drug for treatment of challenging cases of pulmonary infections with bacteria P. aeruginosa, particularly in FC patients where the bacteria showed resistance to traditional antibiotics. In the near future, the team of scientists involved in this project plan to disclose the details of their findings in an academic publication.

Get the full story at